Search
cobicistat (GS-9350, COBI)
Indications:
- treatment of HIV1 in combination with HIV medications that require boosting
- component of elvitegravir/emtricitabine/cobicistat/tenofovir (Quad)
Contraindications:
- not recommended if creatinine clearance < 70 mL/min
Dosage:
- 150 mg, once a day PO QD
Adverse effects:
- diarrhea, nausea
- dyslipidemia: hypercholesterolemia, hypertriglyceridemia
- increases in serum creatine kinase
- increases in serum creatinine
- decreases tubular secretion, not GFR [4]
- expect increase in serum creatinine
- average increase = 0.14 mg/dL
- investigate for other causes if increase > 0.4 mg/dL [4]
- hematuria
Drug interactions:
- inhibits CYP3A4 & other cyt P450s
Mechanism of action:
- inhibits metabolism of other antiretroviral agents used in combination
- inhibits CYP3A4 & other cyt P450s [2]
Interactions
drug adverse effects of antiretroviral agents
General
antiretroviral booster
Database Correlations
PUBCHEM cid=25151504
References
- Wikipedia: Cobicistat
http://en.wikipedia.org/wiki/Cobicistat
- AIDSMEDS
http://www.aidsmeds.com/archive/cobicistat_2301.shtml
- Positively Aware
http://www.positivelyaware.com/2012/12_02/drugs/cobicistat.shtml
- Medical Knowledge Self Assessment Program (MKSAP) 17,
American College of Physicians, Philadelphia 2015
Component-of
atazanavir/cobicistat (Evotaz)
cobicistat/darunavir
cobicistat/darunavir/emtricitabine/tenofovir
cobicistat/elvitegravir/emtricitabine/tenofovir (Quad, Stribild, Genvoya)